Education
About Us
Working with TipRanks
Follow Us
IQVIA Holdings Inc (IQV)
NYSE:IQV
IQV Stock Chart & Stats
$192.67
-$0.07(-0.03%)
At close: 4:00 PM EST
$192.67
-$0.07(-0.03%)
Day’s Range― - ―
52-Week Range$134.65 - $247.05
Previous CloseN/A
Volume300.39K
Average Volume (3M)1.50M
Market Cap
$32.81B
Enterprise Value$44.59B
Total Cash (Recent Filing)$2.14B
Total Debt (Recent Filing)$16.17B
Price to Earnings (P/E)24.5
Beta0.86
Next Earnings
Apr 23, 2026EPS Estimate
2.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.42
Shares Outstanding170,300,000
10 Day Avg. Volume2,486,466
30 Day Avg. Volume1,503,094
Financial Highlights & Ratios
PEG Ratio6.34
Price to Book (P/B)5.96
Price to Sales (P/S)2.38
P/FCF Ratio18.89
Enterprise Value/Market Cap1.36
Enterprise Value/Revenue2.73
Enterprise Value/Gross Profit10.40
Enterprise Value/Ebitda12.87
Forecast
1Y Price Target
$236.69Price Target Upside22.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Bookings And Backlog RecoveryImproving research and development bookings and a book-to-bill ratio above parity, along with fewer large-client cancellations, indicate potential acceleration in backlog conversion and contract research revenue.
Commercial AI Product TractionDeployment of commercialization-ready AI agents gaining traction with pharmaceutical clients points to new higher-value revenue streams beyond traditional clinical services.
Proprietary Data AdvantageIQVIA's global, proprietary healthcare dataset combined with specialized cleaning and integration processes creates a hard-to-replicate asset that supports differentiated AI products and strengthens pricing power.
Bears Say
AI-driven Automation RiskStandard AI could replace routine lower-level tasks, creating downside risk to parts of service revenue if growth in higher-value offerings does not offset automation effects.
Interest Expense And Guidance ShortfallElevated interest expense that weighed on earnings guidance may keep profitability expectations subdued and put continued pressure on investor sentiment until leverage is reduced.
Margin Pressure From Mix And Pass-through CostsA shift toward more pass-through work and lower-margin real-world evidence offerings, combined with currency and product mix effects, may compress operating margins despite top-line growth.
IQVIA Holdings News
IQV FAQ
What was IQVIA Holdings Inc’s price range in the past 12 months?
IQVIA Holdings Inc lowest stock price was $134.65 and its highest was $247.04 in the past 12 months.
What is IQVIA Holdings Inc’s market cap?
IQVIA Holdings Inc’s market cap is $32.81B.
When is IQVIA Holdings Inc’s upcoming earnings report date?
IQVIA Holdings Inc’s upcoming earnings report date is Apr 23, 2026 which is in 70 days.
How were IQVIA Holdings Inc’s earnings last quarter?
IQVIA Holdings Inc released its earnings results on Feb 05, 2026. The company reported $3.42 earnings per share for the quarter, beating the consensus estimate of $3.398 by $0.022.
Is IQVIA Holdings Inc overvalued?
According to Wall Street analysts IQVIA Holdings Inc’s price is currently Undervalued.
Does IQVIA Holdings Inc pay dividends?
IQVIA Holdings Inc does not currently pay dividends.
What is IQVIA Holdings Inc’s EPS estimate?
IQVIA Holdings Inc’s EPS estimate is 2.83.
How many shares outstanding does IQVIA Holdings Inc have?
IQVIA Holdings Inc has 170,300,000 shares outstanding.
What happened to IQVIA Holdings Inc’s price movement after its last earnings report?
IQVIA Holdings Inc reported an EPS of $3.42 in its last earnings report, beating expectations of $3.398. Following the earnings report the stock price went down -10.655%.
Which hedge fund is a major shareholder of IQVIA Holdings Inc?
Currently, no hedge funds are holding shares in IQV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
IQVIA Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$236.69 (22.85% Upside)
$236.69 (22.85% Upside)
Blogger Sentiment
Bullish
IQV Sentiment 75%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 2.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $8.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.2%
Last 30 Days ▼ 5.6%
Last 30 Days ▼ 5.6%
News Sentiment
Bullish
Bullish news 64%
Bearish news 36%
Bearish news 36%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.43%
12-Months-Change
Fundamentals
Return on Equity
21.64%
Trailing 12-Months
Asset Growth
11.32%
Trailing 12-Months
Company Description
IQVIA Holdings Inc
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
IQV Company Deck
IQV Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call presented solid demand recovery (strong bookings, record backlog), healthy revenue and EPS growth, robust cash generation, and constructive FY2026 guidance alongside strategic AI and M&A investments. Offsetting risks discussed included slightly elevated cancellations, margin pressure driven by pass‑throughs and product mix, and elevated leverage with higher interest expense. On balance, management portrayed confidence in secular growth drivers and positioning to monetize AI and integrated offerings.View all IQV earnings summariesIQV Revenue Breakdown
39.99% Technology & Analytics Solutions
55.35% Research & Development Solutions
4.66% Contract Sales & Medical Solutions
IQV Stock 12 Month Forecast
Average Price Target
$236.69
▲(22.85% Upside)
Technical Analysis
Ownership Overview
0.89% Insiders
26.53% Mutual Funds
0.45% Other Institutional Investors
48.15% Public Companies and
Individual Investors